Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (81-90 of 791) with videos related to

Pageof 80
Sort By:
Seminars in Hematology|September 30, 2010
Third-generation tyrosine kinase inhibitors and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Current Oncology Reports|August 3, 2021
The Care of the Leukemic Patients in Times of SARS-CoV-2Nabin Raj Karki, Thuy Le, Jorge Cortes
American Journal of Hematology|November 6, 2018
Treatment-free remission with first- and second-generation tyrosine kinase inhibitorsJorge Cortes, Delphine Rea, Jeffrey H Lipton
Future Oncology (London, England)|December 13, 2006
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Leukemia & Lymphoma|April 25, 2007
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Expert Opinion on Drug Safety|April 9, 2013
Cardiovascular toxicity of tyrosine kinase inhibitorsElie Mouhayar, Jean-Bernard Durand, Jorge Cortes
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2013
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approvalHagop M Kantarjian, Susan O'Brien, Jorge Cortes
Nature Reviews. Clinical Oncology|August 5, 2009
Imatinib and beyond--exploring the full potential of targeted therapy for CMLAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cureJorge Cortes, John M Goldman, Timothy Hughes
Expert Review of Anticancer Therapy|April 2, 2004
Novel therapies for patients with chronic myeloid leukemiaFrancis J Giles, Hagop Kantarjian, Jorge Cortes
Pageof 80

Showing results (81-90 of 791) with videos related to

Sort By:
Pageof 80
Seminars in Hematology|September 30, 2010
Third-generation tyrosine kinase inhibitors and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Current Oncology Reports|August 3, 2021
The Care of the Leukemic Patients in Times of SARS-CoV-2Nabin Raj Karki, Thuy Le, Jorge Cortes
American Journal of Hematology|November 6, 2018
Treatment-free remission with first- and second-generation tyrosine kinase inhibitorsJorge Cortes, Delphine Rea, Jeffrey H Lipton
Future Oncology (London, England)|December 13, 2006
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Leukemia & Lymphoma|April 25, 2007
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Expert Opinion on Drug Safety|April 9, 2013
Cardiovascular toxicity of tyrosine kinase inhibitorsElie Mouhayar, Jean-Bernard Durand, Jorge Cortes
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2013
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approvalHagop M Kantarjian, Susan O'Brien, Jorge Cortes
Nature Reviews. Clinical Oncology|August 5, 2009
Imatinib and beyond--exploring the full potential of targeted therapy for CMLAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cureJorge Cortes, John M Goldman, Timothy Hughes
Expert Review of Anticancer Therapy|April 2, 2004
Novel therapies for patients with chronic myeloid leukemiaFrancis J Giles, Hagop Kantarjian, Jorge Cortes
Pageof 80